CathWorks is a medical technology company that focuses on optimizing Coronary Artery Disease (CAD) therapy decisions through its advanced computational science platform. The company's main product, the FFRangio System, provides a quick, reliable intraprocedural physiologic assessment for the entire coronary tree, aiding physicians in making objective, wire-free FFR-guided PCI decisions. CathWorks primarily serves the healthcare industry, particularly in the field of cardiology. It was founded in 2013 and is based in Kfar-Saba, Israel.
CathWorks's Product Videos
CathWorks's Products & Differentiators
The CathWorks FFRangio™ System uses AI and brings you the definitive benefits of FFR on a quick, non-invasive platform, complete with accurate multi-vessel physiologic and anatomic insights to optimize and confirm PCI decisions for more patients.
Research containing CathWorks
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned CathWorks in 1 CB Insights research brief, most recently on Dec 21, 2022.
CathWorks has filed 39 patents.
Vascular diseases, Cardiac procedures, Cardiovascular physiology, Vascular surgery, Cardiology
Vascular diseases, Cardiac procedures, Cardiovascular physiology, Vascular surgery, Cardiology
Latest CathWorks News
Dec 8, 2023
| Updated InsightAce Study News provided by Share this article Share toX JERSEY CITY, N.J., Dec. 8, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on " Global Cardiac AI Monitoring and Diagnostics Market Size, Share & Trends Analysis Report By Product (Software and Hardware), By Type (Imaging, ECG-based, Cardiac Monitoring, and Others), By Application (Cardiac Arrhythmias, Cardiac Stroke, Ischemic Heart Disease/CAD, and Others), By End Users (Hospitals, Diagnostic Centers, and Other End Users) Market Outlook And Industry Analysis 2031" According to the latest research by InsightAce Analytic, the global Cardiac AI Monitoring and Diagnostics Market size is valued at US$ 1.04 Bn in 2022, and it is expected to reach US$ 7.78 Bn in 2031, recording a promising CAGR of 25.24% during the forecast period of 2023-2031. Cardiac AI Monitoring and Diagnostics Market Report Scope Report Attribute USD 1.04 Bn Quantitative Units Historic Year Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends Segments Covered Regional Scope Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia Competitive Landscape Aidoc, Tempus Labs, Canon, Inc., Circle Cardiovascular Imaging Inc., General Electric Company, HeartFlow, Inc., iRhythm Technologies, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Viz.ai, Ultromics, Ltd., Ultromics, Ltd., Cathworks, Boston Scientific Corporation, and others. Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1952 The future of cardiology will depend on many new technologies, including artificial intelligence (AI), precision medicine and the Internet of Things (IoT). AI/ML has increasingly been used to detect and diagnose cardiac diseases. Cardiac AI monitoring and diagnosis include using artificial intelligence (AI) technology in cardiology to help diagnose and monitor various heart diseases. Incorporating advanced AI technologies will offer complete, reliable and accessible care, which can identify patients at an earlier stage of disease and offer the proper care to help save patients' lives. In addition, technology can improve clinical decision-making through real-time data analysis. Cardiac AI diagnostic solutions include AI-integrated hardware solutions, AI-based software solutions, AI-based cardiac monitoring solutions, AI-based ECG devices, etc. The COVID-19 pandemic has highlighted the need for Artificial intelligence (Al) in Cardiology and has accelerated its adoption in hospitals. The impact has also surged the demand for AI solutions to improve the management of patients with cardiovascular disease. Some of the prominent players in the Cardiac AI Monitoring and Diagnostics Market are: Aidoc Market Dynamics: Drivers: The high prevalence of cardiovascular diseases globally, the growing need to improve accuracy in diagnosing heart diseases, the rising demand for effective and cutting-edge devices, and the adoption of advanced technologies in cardiac monitoring & diagnosis are some of the major factors contributing to the growth of the cardiac AI monitoring and diagnostics market. The increasing burden of cardiovascular diseases increases the demand for early detection & diagnosis of cardiac diseases, which will propel business growth in the upcoming years. In addition, launching novel products with new features is expected to support market growth. Furthermore, integrating artificial intelligence (AI) in cardiovascular devices enhances patient care and reduces cardiac patient mortality. Moreover, product innovations & launches, partnerships, collaborations, mergers and acquisitions, and funding are key strategies that players in the cardiac AI monitoring and diagnostics market adopt to improve their overall position in the market. Challenges: Maintaining data privacy is a big challenge in this field. Data protection involves properly handling sensitive data, including personal information or other non-personal data. There is still a lack of regulations on using patient health information generated from consumer devices by third-party companies. Confidentiality is critical to information transfer and sharing. Thus, data protection & privacy concerns are predicted to hamper the business expansion during the forecast period. Regional Trends: North America held the highest Cardiac AI Monitoring and Diagnostics Market revenue share in 2022 and is expected to continue its growth over the projection period. This is due to the fast adoption of cutting-edge technologies, well-established healthcare infrastructure, and the region's rising regulatory approvals of AI-based systems. The Asia Pacific region is anticipated to rise fastest during the forecast period (2023 to 2031). This growth is due to various factors such as the growing heart diseases, the high demand for early disease diagnosis, developing healthcare infrastructure, and the growing collaborations & partnerships activities in this region. Key Developments In The Market: In March 2023, Aidoc, the leading provider of healthcare AI solutions, introduced its premier, first-of-its-kind cardiovascular AI solutions package. Aidoc's cardiovascular solutions automatically consolidate data, utilize AI to generate clinical insights for more effective diagnosis, and help prevent patients from being lost to follow-up, enabling a possible increase in downstream procedures. In March 2023, Canon Medical Systems supplied two Artificial Intelligence (AI) assisted, spectral, wide-detector CT scanners to Craigavon Area Hospital, stake of Southern Health and Social Care Trust in Northern Ireland, to improve stroke, cancer and cardiac imaging services. In October 2022, Aidoc partnered with Us2.ai to bring its FDA-cleared and CE Marked AI algorithm to analyze and interpret echocardiograms (echo) into its proprietary aiOS™. In July 2022, Medtronic plc partnered with CathWorks to invest in innovative technologies that support physicians and patients from diagnosis to treatment. In July 2021, Canon Medical Systems collaborated with Cleerly to facilitate the simple and efficient use of cardiac computed tomography (CT) to offer a new standard of care for heart disease. Market Segments Software Cardiac Diagnostics Ischemic Heart Diseases/CAD Others Hospitals North America Middle East & Africa U.S. Germany Rest of Europe India Australia & New Zealand Brazil
CathWorks Frequently Asked Questions (FAQ)
When was CathWorks founded?
CathWorks was founded in 2013.
Where is CathWorks's headquarters?
CathWorks's headquarters is located at 3 Rapaport St, Kfar-Saba.
What is CathWorks's latest funding round?
CathWorks's latest funding round is Corporate Minority.
How much did CathWorks raise?
CathWorks raised a total of $150.8M.
Who are the investors of CathWorks?
Investors of CathWorks include Medtronic, Deerfield Management, BioStar Capital, TriVentures, Quark Venture and 6 more.
Who are CathWorks's competitors?
Competitors of CathWorks include Medipixel and 3 more.
What products does CathWorks offer?
CathWorks's products include FFRangio System.
Compare CathWorks to Competitors
Ethicon operating as a subsidiary of Johnson & Johnson, focuses on advancing surgical care. The company's main offerings include surgical technologies and solutions such as sutures, staplers, energy devices, and digital solutions. It aims to improve and save lives through innovative medical procedures. Ethicon primarily serves the healthcare industry. It was founded in 2010 and is based in Warsaw, Indiana.
Biotronik is a medical device company. It is a medical technology company, providing cardiovascular solutions in the areas of cardiac rhythm management, electrophysiology, and vascular intervention. Its products include Selectra Ic-50-60, Selectra Ic-50-75, Selectra Ic-90-65, and Selectra Ic-90-75. It was founded in 1963 and is based in Berlin, Germany.
Kardium is a medical solutions company that operates in the healthcare industry. The company's main offering is an advanced system for the treatment of atrial fibrillation, which includes features such as single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation, all in a single catheter. This system primarily serves the healthcare sector, particularly in the area of cardiac health. It was founded in 2008 and is based in Burnaby, British Columbia.
VALFIX Medical is a company focused on revolutionizing heart valve surgery within the healthcare industry. The company's main service is the development of a comprehensive transcatheter repair solution, which offers a minimally invasive alternative to traditional open-heart surgery, aiming to alleviate heart failure symptoms. The company primarily serves the healthcare industry, specifically targeting cardiologists and heart failure patients. It was founded in 2019 and is based in Tel Aviv-Yafo, Israel.
LifeScan provides diabetes management and glucose monitoring systems. The company offers a range of diabetes-related products and services, including blood glucose monitoring devices and digital health technologies, test strips, meters, lancing, and more. It primarily provides its service to the healthcare sector. It was founded in 1981 and is based in Malvern, Pennsylvania.
Sherlock Biosciences provides biotherapeutics research and therapy development services. It leverages engineering biology tools, including clustered regularly interspaced short palindromic repeats (CRISPR) and synthetic biology to create molecular diagnostics that can deliver results for a range of needs. It develops a CRISPR-based method to detect and quantify specific genetic sequences named SHERLOCK and a synthetic biology-based molecular diagnostics platform named INSPECTR. Its instrumentation-free platforms are applicable in areas including precision oncology, infection identification, food safety, at-home tests, and disease detection in the field. The company was founded in 2019 and is based in Brighton, Massachusetts.